2Y7S

Structure of a designed meningococcal antigen (factor H binding protein, mutant G1) inducing broad protective immunity


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.9 Å
  • R-Value Free: 0.233 
  • R-Value Work: 0.186 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Rational Design of a Meningococcal Antigen Inducing Broad Protective Immunity.

Scarselli, M.Arico, B.Brunelli, B.Savino, S.Di Marcello, F.Palumbo, E.Veggi, D.Ciucchi, L.Cartocci, E.Bottomley, M.J.Malito, E.Lo Surdo, P.Comanducci, M.Giuliani, M.M.Cantini, F.Dragonetti, S.Colaprico, A.Doro, F.Giannetti, P.Pallaoro, M.Brogioni, B.Tontini, M.Hilleringmann, M.Nardi-Dei, V.Banci, L.Pizza, M.Rappuoli, R.

(2011) Sci.Transl.Med 3: 91RA6

  • DOI: 10.1126/scitranslmed.3002234

  • PubMed Abstract: 
  • The sequence variability of protective antigens is a major challenge to the development of vaccines. For Neisseria meningitidis, the bacterial pathogen that causes meningitis, the amino acid sequence of the protective antigen factor H binding protein ...

    The sequence variability of protective antigens is a major challenge to the development of vaccines. For Neisseria meningitidis, the bacterial pathogen that causes meningitis, the amino acid sequence of the protective antigen factor H binding protein (fHBP) has more than 300 variations. These sequence differences can be classified into three distinct groups of antigenic variants that do not induce cross-protective immunity. Our goal was to generate a single antigen that would induce immunity against all known sequence variants of N. meningitidis. To achieve this, we rationally designed, expressed, and purified 54 different mutants of fHBP and tested them in mice for the induction of protective immunity. We identified and determined the crystal structure of a lead chimeric antigen that was able to induce high levels of cross-protective antibodies in mice against all variant strains tested. The new fHBP antigen had a conserved backbone that carried an engineered surface containing specificities for all three variant groups. We demonstrate that the structure-based design of multiple immunodominant antigenic surfaces on a single protein scaffold is possible and represents an effective way to create broadly protective vaccines.


    Organizational Affiliation

    Novartis Vaccines and Diagnostics S.r.l., Via Fiorentina 1, 53100 Siena, Italy.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
FACTOR H BINDING PROTEIN
A, B
256Neisseria meningitidis serogroup B (strain MC58)N/A
Find proteins for Q9JXV4 (Neisseria meningitidis serogroup B (strain MC58))
Go to UniProtKB:  Q9JXV4
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.9 Å
  • R-Value Free: 0.233 
  • R-Value Work: 0.186 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 47.480α = 90.00
b = 99.650β = 97.82
c = 58.060γ = 90.00
Software Package:
Software NamePurpose
SCALAdata scaling
PHENIXrefinement
PHASERphasing
MOSFLMdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2011-07-27
    Type: Initial release
  • Version 1.1: 2012-11-21
    Type: Database references, Refinement description, Source and taxonomy